Daily Archives: November 17, 2017

Neuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College of Neuropsychopharmacology Annual Meeting

GERMANTOWN, Md., Nov. 16, 2017 (GLOBE NEWSWIRE) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that data from the Company’s Phase 2 study of NSI-189 in patients with major depressive disorder will be presented at the 56th American College of Neuropsychopharmacology (ACNP) Annual Meeting, which is being held in Palm Springs, California from December 3-7, 2017.

Poster presentation details are as follows:

Title: A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189 Phosphate, a Neurogenic Compound Among Out-Patients with Major Depressive Disorder
Abstract Number: M79
Session Title: Poster Session I
Presenter: George Papakostas, M.D., Massachusetts General Hospital
Date and Time: Monday, December 4, 2017, 5:30 PM – 7:30 PM PT

About Neuralstem
Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. NSI-189 is a small molecule in clinical development for major depressive disorder (MDD) and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment, Type 1 and Type 2 diabetes, and stroke.

NSI-566 is a stem cell therapy being tested for treatment of paralysis in stroke, chronic spinal cord injury (cSCI) and Amyotrophic Lateral Sclerosis (ALS). Neuralstem’s diversified portfolio of product candidates is based on its proprietary neural stem cell technology.

Cautionary Statement Regarding Forward Looking Information
This news release contains “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the Annual Report on Form 10-K for the year ended December 31, 2016, and Form 10-Q for the three and nine months ended September 30, 2017, filed with the Securities and Exchange Commission (SEC), and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.

Contact:

Kimberly Minarovich
Argot Partners (Investor Relations)
212-600-1902
kimberly@argotpartners.com

Sundance Energy Australia Limited Schedules Third Quarter 2017 Earnings Conference Call

DENVER, Nov. 16, 2017 (GLOBE NEWSWIRE) — Sundance Energy Australia Limited (ASX:SEA) (NASDAQ:SNDE) (“Sundance” or the “Company”), a U.S. onshore oil and gas exploration and production company focused in the Eagle Ford in South Texas, announced it will host a conference call to review third quarter results.

Date:   Australia: Tuesday, November 21, 2017 – United States: Monday November 20, 2017

Time:  Australia: 10:00 AM AEDT – United States: 4:00 PM MST

Australian participants Toll Free dial-in: 1 80 0005 989
Australian (Sydney) Local dial-in: 2 82 239 773

Hong Kong Participants Toll Free dial-in: 800 966 253
Hong Kong Local dial-in: 3011 4522

Singapore participants Toll Free dial-in: 800 852 6412
Singapore Local dial-in: 6622 1010

USA participants Toll Free dial-in: (844) 831 3022

Webcast Link: http://www.sundanceenergy.net/events.cfm

All participants will be asked for their full name and company when joining the conference call.

About Sundance Energy Australia Limited
Sundance Energy Australia Limited (“Sundance” or the “Company”) is an Australian-based, independent energy exploration company, with a wholly owned US subsidiary, Sundance Energy Inc., located in Denver, Colorado, USA.

The Company is focused on the acquisition and development of large, repeatable oil and natural gas resource plays in North America. Current activities are focused in the Eagle Ford.  A comprehensive overview of the Company can be found on Sundance’s website at www.sundanceenergy.net.

For more information, please contact:

United States
Eric McCrady, Managing Director
Tel: +1 (303) 543 5703
Australia
Mike Hannell, Chairman
Tel: +61 8 8363 0388